Press Releases
June 28, 2022
Panbela Announces Publication of Preclinical Data Titled: Expanded Potential of the Polyamine Analogue SBP-101 (Diethyl Dihydroxyhomospermine) as a Modulator of Polyamine Metabolism and Cancer Therapeutic
In vitro studies determined that SBP-101 reduced cellular viability across a broad range of cancer cell types, with an exceptionally strong reduction in ovarian adenocarcinoma viability resulting in a 42% increase in median survival in VDID8+ ovarian cancer mouse model.
June 16, 2022
Panbela Therapeutics, Inc. Closes Acquisition of Cancer Prevention Pharmaceuticals, Inc.
May 12, 2022
Panbela Provides Business Update and Reports Q1 2022 Financial Results
April 26, 2022
Panbela Schedules Conference Call on May 12 to Report 2022 Q1 Financial Results
April 12, 2022
Panbela Announces Poster Presentation at American Association for Cancer Research: The potential of spermine analogue SBP-101 (diethyl dihydroxyhomospermine) as a polyamine metabolism modulator in ovarian cancer
View/download poster presentation »
March 24, 2022
Panbela Provides Business Update and Reports Q4 and FY 2021 Financial Results
March 23, 2022
Panbela to Participate in a Panel Discussion: “Pancreatic Cancer- Turning the Tide for One of the Most Challenging Indications in Oncology,” at the Maxim Virtual Growth Conference on March 28 at 12pm ET
March 10, 2022
Panbela to Participate in the 34th Annual Roth Conference
- Panbela management will participate in a fireside chat at the 34th Annual Roth Conference on March 14, 2022, at 11:30AM PT.
- The webcast will be available at: https://wsw.com/webcast/roth43/pbla/1805948
March 8, 2022